Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq:CPRX) today reported that it has closed its underwritten public offering of shares of its common stock. The Company sold 10,000,000 shares of its common stock in the offering at a public offering price of $15.00 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of the Company’s common stock at the public offering price, less underwriting discounts.
Related news for (CPRX)
- Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
- Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
- Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
- Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals